- Top-Line Results from Rolapitant Phase 3 Program to be Announced by Year-End 2013
- Patient Enrollment Ongoing in Phase 3 Trial of Niraparib in Ovarian Cancer
- Phase 3 Trial of Niraparib in Breast Cancer On Track to Begin 2H 2013
- First TSR-011 Clinical Data Accepted for Presentation at ESMO
- Cash and Cash Equivalents Totaled $178 Million as of June 30, 2013
WALTHAM, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today reported financial results for the second quarter of 2013.
"TESARO is well positioned to meet several significant milestones in the second half of this year. We plan to report top-line results from the rolapitant pivotal program by year end, and we remain on track to begin enrollment in a Phase 3 study of niraparib in patients with BRCA-positive breast cancer," said Lonnie Moulder, chief executive officer of TESARO. "In addition, we look forward to continued enrollment in our Phase 3 trial of niraparib for ovarian cancer and to the first presentation of TSR-011 clinical data in September."
- Enrollment continues in each of three Phase 3 trials of rolapitant for the prevention of chemotherapy induced nausea and vomiting (CINV). TESARO anticipates that top-line data from this pivotal program will be announced by year end.
- Results from a pharmacokinetic study of rolapitant were presented at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) International Symposium in Berlin. These data support concomitant administration of rolapitant with other pharmaceutical products that are metabolized by the liver microsomal enzyme CYP3A4, without a requirement for dose adjustment of the co-administered product.
- TESARO's Phase 3 pivotal study of niraparib in patients with high grade serous, platinum-sensitive ovarian cancer, including those with germline BRCA mutations, has begun patient enrollment.
- Clinical site selection is ongoing to support the initiation of a Phase 3 pivotal study of niraparib in breast cancer patients with germline BRCA mutations during the second half of 2013.
- Final Phase 1 results for niraparib were presented at the American Society of Clinical Oncology (ASCO) annual meeting. Data demonstrated a favorable benefit/risk profile and durable responses among heavily pretreated patients with breast and ovarian cancer.
- An abstract describing initial clinical data for TSR-011 has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress in September.
- TESARO reported a net loss of $21.6 million, or $0.67 per share, for the second quarter of 2013, compared to a net loss of $20.2 million, or $21.31 per share, for the second quarter of 2012. The Company's second-quarter 2012 net loss included $7.0 million of acquired in-process R&D expense related to the in-license of niraparib.
- Research and development expenses increased to $18.2 million for the second quarter of 2013, compared to $11.5 million for the second quarter of 2012, driven primarily by expanded activities for our ongoing development programs.
- General and administrative expenses increased to $3.4 million for the second quarter of 2013, compared to $1.7 million for the comparable period in the previous year, primarily as a result of increases in non-cash stock-based compensation and other general and administrative personnel costs.
- Operating expenses as described above include non-cash stock-based compensation expense of $1.6 million for the second quarter of 2013, compared to $0.4 million for the second quarter of 2012.
- As of June 30, 2013, TESARO had $178.1 million in cash and cash equivalents, no debt and 32.6 million outstanding shares of common stock.
- Announce top-line results from the Phase 3 program evaluating oral rolapitant for the prevention of CINV by the end of 2013;
- Advance the clinical development of the rolapitant intravenous (IV) formulation in order to support a future submission for registration concurrent with regulatory approval of the oral formulation;
- Continue enrollment of the Phase 3 trial of niraparib as a potential maintenance therapy for patients with ovarian cancer;
- Initiate a Phase 3 trial of niraparib in breast cancer patients with germline BRCA mutations; and
- Finalize the recommended Phase 2 dose for TSR-011 and initiate Phase 2a expansion cohorts.
|Unaudited Condensed Consolidated Statements of Operations|
|(in thousands, except per share amounts)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Research and development||$11,532||$18,177||$19,682||$34,680|
|General and administrative||1,685||3,412||2,884||5,812|
|Acquired in-process research and development||7,000||--||7,000||--|
|Loss from operations||(20,217)||(21,589)||(29,566)||(40,492)|
|Net loss||$ (20,178)||$ (21,564)||$ (29,507)||$ (40,433)|
|Net loss per share applicable to common stockholders - basic and diluted||$ (21.31)||$ (0.67)||$ (36.11)||$ (1.32)|
|Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted||947||32,336||817||30,577|
|Unaudited Condensed Consolidated Balance Sheets|
|December 31, 2012||June 30, 2013|
|Cash and cash equivalents||$ 125,445||$ 178,091|
|Other current assets||1,175||1,564|
|Total current assets||126,620||179,655|
|Property and equipment, net||219||504|
|Total assets||$ 127,380||$ 181,022|
|Liabilities and stockholders' equity|
|Accounts payable||$ 3,170||$ 1,964|
|Other current liabilities||3||13|
|Total current liabilities||11,718||11,954|
|Other non-current liabilities||--||9|
|Commitments and contingencies|
|Total stockholders' equity||115,662||169,059|
|Total liabilities and stockholders' equity||$ 127,380||$ 181,022|
CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or firstname.lastname@example.org